



1201/8303/001270



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ


REC'D 19 MAY 2003  
WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration, save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name of the company as it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

*R. Mahoney*

Dated 28 April 2003

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

An Executive Agency of the Department of Trade and Industry

**BEST AVAILABLE COPY**

The  
Patent  
OfficeTHE PATENT OFFICE  
25 MAR 2002  
RECEIVED BY FAXThe Patent Office  
Cardiff Road  
Newport  
Gwent NP9 1RH

## Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)

25 MAR 2002

Fee: £0

1. Your reference

44394/JMD

2. Patent application number  
(The Patent Office will fi

0206981.3

25MAR02 E706329-1 001631  
P01/7700 0.00-0206981.33. Full name, address and postcode of the or of  
each applicant (*underline all surnames*)AdProTech Limited  
Chesterford Research Park  
Little Chesterford  
Saffron Walden  
Essex CB10 1XLPatents ADP number (*if you know it*)If the applicant is a corporate body, give the  
country/state of incorporation

UNITED KINGDOM

7936123002

4. Title of the invention

Compounds

5. Full name, address and postcode in the United  
Kingdom to which all correspondence relating  
to this form and translation should be sentAdProTech Limited  
Chesterford Research Park  
Little Chesterford  
Saffron Walden  
Essex CB10 1XLPatents ADP number (*if you know it*)

91001

6. If you are declaring priority from one or more  
earlier patent applications, give the country  
and the date of filing of the or of each of these  
earlier applications and (*if you know it*) the or  
each application number

Country

Priority application  
(*if you know it*)Date of filing  
(day/month/year)7. If this application is divided or otherwise  
derived from an earlier UK application,  
give the number and the filing date of  
the earlier application

Number of earlier application

Date of filing  
(day/month/year)8. Is a statement of inventorship and of right  
to grant of a patent required in support of  
this request? (*Answer 'Yes' if:*

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d))

YES

## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document.

Continuation sheets of this form

Description	15
Claim(s)	4
Abstract	0
Drawing(s)	7

10. If you are also filing any of the following, state how many against each item.

Priority documents	0
Translations of priority documents	0
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	0
Request for preliminary examination and search (Patents Form 9/77)	1
Request for substantive examination (Patents Form 10/77)	0

Patents Form 1/77 (10/77)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date

25 March 2002

Reddie &amp; Grize

12. Name and daytime telephone number of person to contact in the United Kingdom

J M DAVIES  
01223 360350

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or such direction has been revoked.

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
  - If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
  - If you have answered 'Yes' Patents Form 7/77 will need to be filed.
  - Once you have filled in the form you must remember to sign and date it.
  - For details of the fee and ways to pay please contact the Patent Office.

-1-

DUPLICATE

**Compounds.**

This invention relates to compounds, and in particular to polypeptides, their use and methods for their production. These polypeptides are produced from "pseudo-cysteine" amino acids that facilitate the assembly of polypeptides by native chemical ligation.

**Background**

It is known that it is possible to ligate two peptidic or non-peptidic compounds together by a process known as native chemical ligation. The basic requirements for this coupling are the presence on participant A of a thioester moiety such as benzyl or ethyl thioester, and the presence on participant B of an N-terminal cysteine. The coupling reaction commences when the thio-nucleophile initially attacks the thioester in a reversible fashion causing the thioalkyl group to leave. The thioester so formed then undergoes an intramolecular S→N acyl shift to irreversibly produce the ligated amide product A-B with a native cysteine at the junction (Figure 1).

This process can be repeated if it is possible to unmask a further N-terminal cysteine at the N-terminal of A, in the product A-B. This can be achieved by enzymatic means or by classical protecting group chemistry. A further native

chemical ligation coupling with a thioester-containing moiety E would therefore yield the product E-A-B. These methods have been used to generate a variety of proteins.

It is also known that cyclic peptides/proteins can be produced by incorporating both the thioester and amino terminal cysteine (N-terminal cysteine) moieties within the same molecule.

Further, it is possible to perform the ligation described above without removing all of the reaction participants from a solid phase.

A method for incorporating a thioester moiety into a participant where one does not exist is also known. This method relies on the reaction of a primary amine with thiolane-2,5-dione and subsequent alkylation of the thioacid formed with an appropriate alkyl bromide. This method requires a single primary amine to be present otherwise multiple thioesters may be coupled together.

Amino-acid monomer molecules are available with a protected functionality grafted onto another amino acid sidechain. For example, N- $\alpha$ -Fmoc-N- $\beta$ -(N-t-Boc-amino-oxyacetyl)-L-diaminopropionic acid (Novabiochem - San Diego, CA) incorporates a protected oxyamine onto an amino acid sidechain that is capable, after deprotection, of undergoing

-3-

chemoselective ligation to carbonyl containing moieties. However, with reagents currently available it is not possible to incorporate a pseudo C-terminal cysteine into a polypeptide. A C-terminal cysteine is desirable to allow the linking of a molecule to a thioester (*vide supra*) without using an N-terminal cysteine, if for example, the N-terminus is required unmodified for biological activity.

Further, there is no method to enable the ligation of a C-terminal or other thioester with a pseudo C-terminal cysteine.

We have now produced reagents that enable the incorporation onto an amino acid sidechain at the C-terminal end of the peptide, a surrogate 1-amino-2-thiol that would be capable of performing a native chemical ligation.

Further, we have disclosed a method that can be used to introduce a 1-amino-2-thiol group into the side chain of a lysine to enable the conjugate of a polypeptide containing such a residue to be ligated to a target compound using native chemical ligation methods.


#### **Detail of the Invention**

The invention provides a compound comprising a polypeptide, the polypeptide having at a C-terminal end a pseudo amino

-4-

acid, the pseudo amino acid having a side chain containing a 1-amino-2-thiol moiety.

Further it provides a compound having a polypeptide of the structure:




wherein:

R is a polypeptide chain;

X is a linker;

The linker may comprise, for example, methylene units i.e. CH<sub>2</sub> units or may include residues covalently linked by amide, ester, ether, thioether bonds or aryl groups, for example. Further, the linker may be (CH<sub>2</sub>)<sub>n</sub>, where n is 0 to 6, preferably 4.


The invention also provides a protected pseudo amino acid comprising the structure



where the Y is optionally H or other suitable residue and PG1, PG2 and PG3 are different protecting groups.

The protecting groups may be FMOC, BOC or Trt, for example. Other will be known to those skilled in the art.

One suitable protected amino acids is





-6-

which may be produced as described in Example 2 and illustrated in Figure 2.

WO 98/02454 relates to the derivatisation of soluble complement regulators by disulfide exchange reaction with pyridyl disulfide activated myristoyl/electrostatic switch peptides (MSWPs). These derivatives demonstrate improved complement inhibitory activity owing to their membrane localisation by the MSWP. The myristoyl group was designed to be minimally membrane insertive, while the lysine rich peptidic portion of MSWP-1 (Seq. ID No 1) was designed to interact with the negatively charged phospholipid headgroups present on the lipid bilayer. The concept is exemplified in WO 98/02454 by SC1-3 of LHR-A of CR1, altered by a single C-terminal cysteine residue. After treatment with an appropriate reducing agent to ensure the presence of a free thiol on the terminal cysteine sidechain, the protein is reacted with MSWP-1 (N-(Myristoyl)-Gly-Ser-Ser-Lys-Ser-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-Pro-Gly-Asp-(S-2-Thiopyridyl)Cys-NH<sub>2</sub>) (Seq ID No: 1) to yield a membrane binding derivative of SC1-3 (Figure 4). The resultant conjugate protein showed anti-haemolytic activity orders of magnitude greater than that displayed by the underivatised protein alone.

This chemistry relies on the existence within the protein participant of the reaction a single free thiol resulting in derivatisation at a single point only. In other circumstances

-7-

it is desirable to link the class of peptide described to proteinaceous or non-proteinaceous molecules bearing a thioester. In the current design of the peptide, however, an N-terminal myristoyl function is required, thus disallowing the incorporation of an N-terminal cysteine to participate in the ligation reaction.

In order to achieve this, we describe an amino acid monomer capable of participating in standard Fmoc synthesis that would yield, on final deprotection a 1-amino-2-thiol at the c-terminus (Figure 2 and Example 2). When incorporated into a polypeptide containing myristoyl switch type peptide (APT227B - Seq ID No: 2), it was indeed found to be capable of undergoing native chemical ligation to thioester-containing molecules, a vitamin D<sub>3</sub> polypeptide, and an Impact™ expressed protein thioester.

Also disclosed is the incorporation of such a protected sidechain 1-amino-2-thiol into a peptide by the use of orthogonal protecting groups (Example 3).

Where the thioester-containing moiety is a protein, one method of formation of the ligated product of the invention is provided by the IMPACT system (New England Biolabs).

Conjugates are afforded by the native chemical ligation of peptides containing an N-terminal cysteine, to proteins expressed in frame with a controllable intervening peptide

-8-

sequence (CIVPS) and an affinity purification handle. The desired protein is cleaved from its affinity purification matrix by elution with a free thiol such as MESNA to yield a C-terminal thioester. The MESNA thioester is displaced by the thiol of the N-terminal cysteine before an S→N acyl shift installs the peptide bond in an irreversible fashion. Alternatively, the affinity matrix is incubated with the free peptide, displacing the desired protein from the matrix and ligating in a single step.

In the specific case where there is a 1-amino-2-thiol engineered onto a C-terminal sidechain and additionally there is an N-terminal cysteine, (see Figure 3 and Example 4) it is possible to undergo native chemical ligation on both ends of the molecule. If both ends react with the same thioester it is possible to form a homodimer (Figure 4, Example 5). If one 1-amino-2-thiol is reacted first and another after a subsequent purification, heterodimeric structures are possible (Figure 5, Example 6).

It is also possible to incorporate more than one sidechain 1-amino-2-thiol into peptides utilising this technology to allow more than two moieties to be linked (Figure 6 and Example 7). Different lengths and compositions of linker peptide between sidechain 1-amino-2-thiols can be used to afford differing spatial and physicochemical properties.

-9-

It is also possible to introduce other reactive groups for instance an amino-oxy function on the N-terminus to allow chemically orthogonal linking to other molecules after the completion of native chemical ligation.

Any of the components brought together with this enabling technology may be selected from the group consisting of:

A pharmacophore

A ligand

A small molecule

A purification handle/immunochemical tag (eg biotin)

A fluorescent moiety

A chelating agent

A chelating ligand

A chelating ligand plus radioimaging agent

A therapeutic protein

An antibody or fragment thereof

A peptide

This list is not exhaustive. Other moieties may be linked in the fashion to be described and will be apparent to those skilled in the art.

Drawings

Figure 1: Native Chemical Ligation schematic.

-10-

Figure 2: Synthesis of a monomer to allow single-step incorporation of a protected sidechain 1-amino-2-thiol into a peptide by solid phase synthesis.

Figure 3: Structure of dimerisation reagent APT3068.

Figure 4: Preparation of a homodimer using the technology.

Figure 5: Preparation of a heterodimer using the technology.

Figure 6: Structure of trimerisation reagent APT3288.

Figure 7: IMPACT system of preparing polypeptides

Figure 8: Scheme 1 for preparing protected pseudo amino acids.

#### Examples

Example 1: Synthesis of disulfide exchange MSWP1 (SEQ ID NO: 1)

The peptide:

Myristoyl-Gly-Ser-Ser-Lys-Ser-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-Pro-Gly-Asp-Cys-(S-2-thiopyridyl)-NH<sub>2</sub> was synthesised according to the method described in WO 98/02454.

Example 2: Synthesis of protected lysine sidechain 1-amino-2-thiol amino acid monomer

-11-

N- $\alpha$ -Fmoc-N- $\epsilon$ -Boc-L-Lysine (5.14 g) was dissolved in 50/50 DCM/TFA (~20 mL) and stirred for 30 minutes. The solvent was evaporated under reduced pressure and the residual yellow oil was dissolved in water and freeze-dried to remove remaining TFA and furnish N- $\alpha$ -Fmoc-L-Lysine.

A solution of Boc-Cys(Trt)-OH (4.66 g) and N-hydroxysuccinimide (1.15 g) in 1,4-dioxane (20 mL) and DCC (dicyclohexylcarbodiimide) (2.06 g) were stirred overnight. The urea derivative, which precipitated, was filtered off and washed with DCM. Solvent was evaporated and the resulting oil dissolved in ethyl acetate, then washed with sat. sodium carbonate solution then water. After drying over anhydrous sodium sulphate, the solvent was removed under reduced pressure to yield Boc-Cys(Trt)-N-hydroxy succinimide ester.

N- $\alpha$ -Fmoc-L-Lysine above was dissolved in DCM (20 mL) and the Boc-Cys(Trt)-N-hydroxysuccinimide ester above dissolved in DMF (30 mL) and DCM (10 mL). The solutions were mixed and DIPEA added until pH 7. The mixture was stirred overnight at ambient temperature. After this time, half the solvent was removed under reduced pressure and ethyl acetate (200 mL) added. The organic mixture was washed with water (100 mL), sodium bicarbonate (200 mL), and water (100 mL). The organic layer was dried over anhydrous sodium sulphate and evaporated

to yield a cream coloured foam. The product was purified using silica gel chromatography using 5:1 ethyl acetate/petroleum ether 40-60 to afford the product as a pale cream foam.

**Example 3: Synthesis of Native Chemical Ligation peptide**

**MSWP2278 (SEQ ID NO: 2)**

The peptide:

Myristoyl-Gly-Ser-Ser-Lys-Ser-Pro-Ser-Lys-Lys-Asp-Asp-Lys-Lys-Pro-Gly-Asp-( $\epsilon$ -amino-cysteinyl carboxamide)-Lys-NH<sub>2</sub> was prepared by solid phase synthesis using Boc synthesis on MBHA resin (Nova). Coupling reactions were carried out using appropriately protected Boc amino acid monomers (Nova) activated with TBTU aided with N,N'-dimethylacetamide (Bio. Co.) with ninhydrin monitoring after each coupling. The first amino acid was installed as  $\alpha$ -amino-Boc,  $\epsilon$ -amino-Fmoc lysine, and the Fmoc protection then removed with 20% piperidine.  $\alpha$ -Amino-Fmoc, S-methoxybenzyl cysteine was then coupled to the  $\epsilon$ -amino group before the remainder of the synthesis was carried out using appropriately protected Boc monomers. Cleavage from the resin and cleavage of the sidechain protecting groups was accomplished with high HF conditions using p-cresol and p-thiocresol as scavengers at 0°C over 1 h.

The crude peptide was desalted via gel filtration (Sephadex G10, 0.1% TFA in water) before purification by preparative C18 Vydac) high performance liquid chromatography (HPLC) using

-13-

0.1% trifluoroacetic acid and 0.1% trifluoroacetic acid/90% acetonitrile as gradient components. After lyophilisation, the peptide was a white amorphous powder, soluble to at least 10 mg/mL in both dimethylsulfoxide and water. Fast atom bombardment spectrometry gave a main peak at 2101 amu corresponding to the molecular ion of the peptide.

**Example 4: Synthesis of dimerisation reagent (APT3068) (Figure 3)**

Standard Fmoc solid phase synthesis was utilised on Rink amide resin. Monomer was coupled first followed by Fmoc-9-aminononanoic acid followed by Boc-Cys(Trt)-OH. After cleavage from the resin and removal of all protecting groups using TFA (95/5/5) the crude linker was ether precipitated and purified by preparative C18-reverse phase HPLC. ESMS 507.2 (M+H).

**Example 5: Formation of a homodimer using native chemical ligation**

A solution of APT3068 in water (37.5 mM, 21.3 uL) was added to a solution of TCEP (tris-2-carboxyethyl phosphine) (1 equiv.) in HEPES buffer (pH 8.5, 40 mM, 265 uL). A solution of APT2501 (10 mg/mL, 140 uL) was then added. The reaction mixture was left at ambient temperature overnight and then analysed by HPLC. The doubly ligated product eluted slightly



-14-

later than APT2501 and was found to be a 2/1 ligation product by MALDI MS - 4378. This product was purified by preparative HPLC and lyophilised.

**Example 6: Formation of a heterodimer using native chemical ligation**

A solution of APT3068 in water (37.5 mM, 21.3 uL) was added to a solution of TCEP (tris-2-carboxyethyl phosphine) (1 equiv.) in HEPES buffer (pH 8.5, 40 mM, 265 uL). A solution of APT2501 (1 mg/mL, 140 uL) was then added. The reaction mixture was left at ambient temperature overnight and then analysed by HPLC. The ligated product eluted slightly later than APT2501 and was found to be a 1/1 ligation product by ESMS - 2444 (M+H). This product was purified by preparative HPLC and lyophilised. This product was a mixture of two products with single ligation to one or other of the 1-amino-2-thiols. These products are functionally equivalent and have identical molecular weight. Figure 5 shows only one of these two products for the sake of brevity.

EGFP MESNA thioester lyophilisate was dissolved in HEPES buffer (pH 8.5 40 mM, 250 uL) and added to a solution of TCEP (tris-2-carboxyethyl phosphine) (1 equiv.) in HEPES buffer (pH 8.5, 40 mM, 265 uL). A solution of the singly ligated product described above in the same buffer (25 fold molar excess) was then added and the mixture incubated overnight at ambient

-15-

temperature. SDS PAGE showed clear and quantitative conversion of the protein thioester to a ligated product approximately 2 kDa higher in molecular weight.

**Example 7: Formation of a trimerisation reagent (APT3288)**


Standard Fmoc solid phase synthesis was utilised on Rink amide resin. Monomer was coupled first followed by Fmoc-6-aminocaproic acid (twice) followed by Monomer. Two further additions of Fmoc-6-aminocaproic acid and one of Boc-Cys(Trt)-OH completed the synthesis. After cleavage from the resin and removal of all protecting groups using TFA/EDT/TIPS (95/5/5) the crude linker was ether precipitated and purified by preparative C18-reverse phase HPLC. ESMS 1035.4 (M<sup>+</sup>).

-16-

**Claims**

1. A compound comprising a polypeptide, the polypeptide having at a C-terminal end a pseudo amino acid, the pseudo amino acid having a side chain containing a 1-amino-2-thiol moiety.

2. A compound according to claim 1 wherein the polypeptide comprises the structure:



wherein:


R is a polypeptide chain;

X is a linker.

3. A compound according to claim 2 wherein the linker comprises (CH<sub>2</sub>)<sub>n</sub>, where n is 0 to 6, preferably 4.

4. A protected pseudo amino acid comprising the structure

-17-




wherein:

Y is optionally H or other suitable residue; and  
PG<sub>1</sub>, PG<sub>2</sub> and PG<sub>3</sub> are different protecting groups.

5. A protected pseudo amino acid according to claim 3 wherein the protecting groups are selected from the listed consisting of FMOC, BOC or Trt.

6. A protected pseudo amino acid according to claim 5 having the structure:

-18-



7. A process of producing a pseudo cysteine comprising the steps according to Figure 2.

8. A pseudo cysteine obtained by the method of claim 4.

9. A pseudo cysteine obtainable by the method of claim 4.

10. The use of a polypeptide of claim 1-2, a pseudo amino acid of claim 3 or a pseudo cysteine of claim 5-6, for producing a peptide or a protein by native chemical ligation.

11. The use of a polypeptide of claim 1-2, a pseudo amino acid of claim 3 or a pseudo cysteine of claim 5-6, for producing a homodimer.


-19-

12. The use of a polypeptide of claim 1-2, a pseudo amino acid of claim 3 or a pseudo cysteine of claim 5-6, for producing a heterodimer.

13. The use of a polypeptide of claim 1-2, a pseudo amino acid of claim 3 or a pseudo cysteine of claim 5-6, for producing an oligomer.

-20-

Figure 1:








-22-


Figure 3:






-24-

Figure 5:



-25-

Figure 6:



-26-

Figure 7

